NDA 021344 · Astrazeneca
Faslodex
Fulvestrant · Intramuscular · Estrogen Receptor Antagonist
NovelLast checked: Nov 19, 2026Latest source record: Jan 19, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Apr 25, 2002
Approved uses
13
Original approval plus efficacy supplements
Registered trials
557
100 Phase 3, 120 recruiting
FAERS reports
33,513
27,136 serious, 5,028 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 25, 2020.
Monotherapy FASLODEX is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy FASLODEX is indicated for the treatment of: • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. FASLODEX is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. (1)
Mechanism: Many breast cancers have estrogen receptors (ER) and the growth of these tumors can be stimulated by estrogen. Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells. In vitro studies demonstrated that fulvestrant is a reversible inhibitor of the growth of tamoxifen-resistant, as well as estrogen-sensitive human breast cancer (MCF-7) cell lines. In in vivo tumor studies, fulvestrant delayed the establishment of tumors from xenografts...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 28, 2020 Supplement 42 · Efficacy LetterLabel
- May 13, 2020 Supplement 41 · Efficacy LabelLetter
- Nov 21, 2019 Supplement 38 · Efficacy LabelLetter
- Mar 11, 2019 Supplement 37 · Efficacy · priority review LabelLetter
- Jul 5, 2018 Supplement 36 · Efficacy LetterLabel
- Nov 14, 2017 Supplement 35 · Efficacy · priority review LabelLetter
- Aug 25, 2017 Supplement 34 · Efficacy LetterLabel
- Mar 2, 2016 Supplement 26 · Efficacy ReviewLetterLabel
- Nov 9, 2012 Supplement 20 · Efficacy · priority review LetterReviewLabel
- May 17, 2011 Supplement 13 · Efficacy · priority review Pediatric Medical ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Sep 9, 2010 Supplement 12 · Efficacy LetterReviewLabel
- Dec 24, 2003 Supplement 1 · Efficacy LabelLetter
- Apr 25, 2002 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
2 products under this application
- FASLODEX · FULVESTRANT 250MG/5ML (50MG/ML) · SOLUTION, INTRAMUSCULAR · Prescription · TE AO
- FASLODEX · FULVESTRANT 125MG/2.5ML (50MG/ML) · SOLUTION, INTRAMUSCULAR · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fulvestrant" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyPivotal-lookingRecruiting
Fujian Cancer HospitalGovernment (non-federal)
NCT07581834 · 2,000 participants (planned) · Start Jan 21, 2026 · Primary completion Dec 31, 2031
Drug: Dalpiciclib 125mg; Dalpiciclib 100mg and 1 more · For: Breast Diseases; Breast Neoplasms; Dalpiciclib and 3 more
Sites: Fuzhou, China; Chengdu, China
- Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryPivotal-lookingActive, not recruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT01953588 · 1,473 participants · Start Feb 27, 2014 · Primary completion Apr 1, 2027
Drug: fulvestrant; anastrozole · For: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma and 6 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 860 sites in all
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)Pivotal-lookingRecruiting
Celcuity IncIndustry
NCT06757634 · 1,180 participants (planned) · Start Jul 24, 2025 · Primary completion Mar 31, 2029
Drug: Arm A: Gedatolisib + Palbociclib + Fulvestrant; Arm B: Ribociclib + Fulvestrant and 2 more · For: Breast Cancer
Sites: Jonesboro, Arkansas; Little Rock, Arkansas; Duarte, California · 239 sites in all
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT06341894 · 1,163 participants (planned) · Start Nov 17, 2023 · Primary completion Jun 2027
Drug: Dalpiciclib; Endocrine therapy · For: Early Breast Cancer
Sites: Nanjing, China
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT03182634 · 1,150 participants (planned) · Start Dec 15, 2016 · Primary completion Nov 2022
Drug: Fulvestrant; Neratinib and 3 more · For: Advanced Breast Cancer
Sites: Sutton, United Kingdom; Bournemouth, United Kingdom; Bristol, United Kingdom · 19 sites in all
- Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase InhibitorPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01610284 · 1,147 participants · Start Aug 7, 2012 · Primary completion Apr 29, 2015
Drug: Fulvestrant; BKM120 and 1 more · For: Breast Cancer
Sites: Mobile, Alabama; Phoenix, Arizona; Fayetteville, Arkansas · 268 sites in all
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03424005 · 1,132 participants (planned) · Start Mar 30, 2018 · Primary completion Sep 30, 2030
Drug: Capecitabine; Atezolizumab and 21 more · For: Metastatic Breast Cancer
Sites: Duarte, California; Irvine, California; La Jolla, California · 55 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression4,341
- fatigue4,249
- nausea3,085
- death2,782
- diarrhoea2,684
- neutropenia2,542
- white blood cell count decreased2,247
- metastases to bone2,179
- neoplasm progression2,130
- asthenia1,812
- pain1,786
- metastases to liver1,779
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 63 |
| 2005 | 115 |
| 2006 | 128 |
| 2007 | 149 |
| 2008 | 166 |
| 2009 | 158 |
| 2010 | 141 |
| 2011 | 268 |
| 2012 | 541 |
| 2013 | 343 |
| 2014 | 346 |
| 2015 | 713 |
| 2016 | 1,522 |
| 2017 | 2,213 |
| 2018 | 2,278 |
| 2019 | 2,870 |
| 2020 | 3,607 |
| 2021 | 3,353 |
| 2022 | 3,238 |
| 2023 | 3,862 |
| 2024 | 2,760 |
| 2025 | 2,874 |
| 2026 | 1,805 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Faslodex (Fulvestrant)
2024 spending
$326K
Beneficiaries
28
176 claims
Per beneficiary
$11,654
$182.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,642,589 |
| 2021 | $670,070 |
| 2022 | $444,289 |
| 2023 | $293,278 |
| 2024 | $326,309 |
Part B: Faslodex* (Fulvestrant*) · HCPCS J9395
2024 spending
$21.9M
Beneficiaries
17,770
135,166 claims
Per beneficiary
$1,232
2024 ASP limit $8.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $169,176,633 |
| 2021 | $99,529,826 |
| 2022 | $38,648,983 |
| 2023 | $27,127,870 |
| 2024 | $21,891,999 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.
Turner NC, Im SA, Saura C, et al. · N Engl J Med 2024 · Clinical Trial, Phase II, Comparative Study
- Management of androgenic alopecia: a systematic review of the literature.
Rosenthal A, Conde G, Greco JF, et al. · J Cosmet Laser Ther 2024 · Systematic Review
- Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.
Kalinsky K, Bianchini G, Hamilton E, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
Campone M, De Laurentiis M, Jhaveri K, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
Jhaveri KL, Im SA, Saura C, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.